Studies have demonstrated that nasal vaccination with CAF01-based vaccines for the prevention of influenza or Streptococcus pyogenes was effective in inducing the production of mucosal effector T cells and IgA immune responses and also protected the vaccinated model animals. This evidence concerns the gene CD79A and influenza.